Radiopharm Theranostics (RADX) Cost of Revenue (2025 - 2026)
Radiopharm Theranostics' Cost of Revenue was $17,010 in FY2026 (year ended Jun 30, 2026), down 99.5% from $3.59 million in FY2025.
Powered by 
Analysis
Radiopharm Theranostics (RADX) Cost of Revenue (2025 - 2026) Analysis & Trends
- Per Business Quant data, Cost of Revenue in earlier fiscal years was $3.59 million in FY2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 3.27 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 8.05 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 4.29 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 4.40 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.71 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.52 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.81 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 1.58 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.09 Bn |
| 10 | Radiopharm Theranostics | 5.03 Bn | 5.00 Bn | 186,835.86 | 1.78 Mn |
API Access
Radiopharm Theranostics Cost of Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=RADX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cost-of-revenue", "ticker": "RADX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=RADX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();